{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:12Z","timestamp":1793506332368,"version":"4.5.0"},"reference-count":342,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":111,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Immunology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.smim.2020.101430","type":"journal-article","created":{"date-parts":[[2020,11,29]],"date-time":"2020-11-29T00:03:21Z","timestamp":1606608201000},"page":"101430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":116,"special_numbering":"C","title":["New viral vectors for infectious diseases and cancer"],"prefix":"10.1016","volume":"50","author":[{"given":"Emanuele","family":"Sasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Morena","family":"D\u2019Alise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Scarselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Folgori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"34","key":"10.1016\/j.smim.2020.101430_bib0005","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1073\/pnas.1400472111","article-title":"History of vaccination","volume":"111","author":"Plotkin","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"51","key":"10.1016\/j.smim.2020.101430_bib0010","doi-asserted-by":"crossref","first-page":"12868","DOI":"10.1073\/pnas.1717157115","article-title":"Antimicrobial resistance and the role of vaccines","volume":"115","author":"Bloom","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10068","key":"10.1016\/j.smim.2020.101430_bib0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/14760584.2016.1124762","article-title":"Molecular mechanisms for enhanced DNA vaccine immunogenicity","volume":"15","author":"Li","year":"2016","journal-title":"Expert Rev. Vaccines"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0025","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"46","key":"10.1016\/j.smim.2020.101430_bib0030","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1016\/j.vaccine.2016.09.062","article-title":"Delivery methods to increase cellular uptake and immunogenicity of DNA vaccines","volume":"34","author":"Jorritsma","year":"2016","journal-title":"Vaccine"},{"issue":"36","key":"10.1016\/j.smim.2020.101430_bib0035","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.smim.2020.101430_bib0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"115","key":"10.1016\/j.smim.2020.101430_bib0050","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003155","article-title":"Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man","volume":"4","author":"Barnes","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0055","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1038\/s41598-018-21630-4","article-title":"Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP","volume":"8","author":"Bliss","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: an historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0065","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0070","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0378-1119(83)90163-4","article-title":"Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA","volume":"25","author":"Smith","year":"1983","journal-title":"Gene"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0075","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/mt.2014.15","article-title":"Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates","volume":"22","author":"Capone","year":"2014","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0080","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Gomez","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"issue":"30","key":"10.1016\/j.smim.2020.101430_bib0085","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1016\/j.vaccine.2006.11.066","article-title":"Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform","volume":"25","author":"Poulet","year":"2007","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.smim.2020.101430_bib0090","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0095","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/COH.0000000000000362","article-title":"Lessons learned from human HIV vaccine trials","volume":"12","author":"Pollara","year":"2017","journal-title":"Curr. Opin. HIV AIDS"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0100","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1084\/jem.20040874","article-title":"CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract","volume":"200","author":"Brenchley","year":"2004","journal-title":"J. Exp. Med."},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib0105","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.1128\/JVI.00788-11","article-title":"DNA\/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa","volume":"85","author":"Perreau","year":"2011","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib0110","first-page":"479","article-title":"[Comparative experimental works on cow pox virus vaccines]","volume":"138","author":"Herrlich","year":"1954","journal-title":"Arch. Hyg. Bakteriol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0115","first-page":"24","article-title":"[Changes in the vaccinia virus through continuing passages in chick embryo fibroblast cultures]","volume":"195","author":"Mayr","year":"1964","journal-title":"Zentralbl. Bakteriol. Orig."},{"issue":"35","key":"10.1016\/j.smim.2020.101430_bib0120","first-page":"1149","article-title":"[Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus (\u201cMVA virus\u201d)]","volume":"113","author":"Stickl","year":"1971","journal-title":"Munch. Med. Wochenschr."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"issue":"22","key":"10.1016\/j.smim.2020.101430_bib0130","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0135","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/0264-410X(94)90341-7","article-title":"A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus","volume":"12","author":"Sutter","year":"1994","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.smim.2020.101430_bib0140","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1817307","article-title":"Phase 3 efficacy trial of Modified Vaccinia Ankara as a vaccine against smallpox","volume":"381","author":"Pittman","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0145","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0150","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","article-title":"Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara","volume":"171","author":"Goonetilleke","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0155","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1128\/IAI.73.6.3814-3816.2005","article-title":"Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs","volume":"73","author":"Williams","year":"2005","journal-title":"Infect. Immun."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0160","doi-asserted-by":"crossref","first-page":"e5264","DOI":"10.1371\/journal.pone.0005264","article-title":"MVA.85A boosting of BCG and an attenuated, phoP deficient M. Tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques","volume":"4","author":"Verreck","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.smim.2020.101430_bib0165","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1128\/IAI.00287-09","article-title":"Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis","volume":"77","author":"Vordermeier","year":"2009","journal-title":"Infect. Immun."},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0170","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/infdis\/jir195","article-title":"Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants","volume":"203","author":"Scriba","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"9871","key":"10.1016\/j.smim.2020.101430_bib0175","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088340","article-title":"MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses","volume":"9","author":"Hessel","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/ciq015","article-title":"Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1","volume":"52","author":"Berthoud","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0190","article-title":"Safety and immunogenicity of the heterosubtypic influenza a vaccine MVA-NP+M1 manufactured on the AGE1.CR.pIX avian cell line","volume":"7","author":"Folegatti","year":"2019","journal-title":". Vaccines (Basel)"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048322","article-title":"A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years","volume":"7","author":"Antrobus","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0200","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/cid\/cis327","article-title":"Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans","volume":"55","author":"Lillie","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.smim.2020.101430_bib0205","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.19090.1","article-title":"A phase IIb study to determine the safety and efficacy of candidate INfluenza Vaccine MVA-NP+M1 in combination with licensed Ina CTivated infl Uenza vaccine in adult S aged 65 years and above (INVICTUS): a study protocol","volume":"8","author":"Swayze","year":"2019","journal-title":"F1000Res"},{"issue":"22","key":"10.1016\/j.smim.2020.101430_bib0210","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1056\/NEJM198011273032204","article-title":"The confirmation and maintenance of smallpox eradication","volume":"303","author":"Breman","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"261","key":"10.1016\/j.smim.2020.101430_bib0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009185","article-title":"A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory","volume":"6","author":"Swadling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101430_bib0220","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-12-801238-3.00086-6","article-title":"Adenoviruses","author":"Kajon","year":"2019","journal-title":"Reference Module in Biomedical Sciences"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0225","first-page":"7909","article-title":"The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups","volume":"72","author":"Roelvink","year":"1998","journal-title":"A, C, D, E, and F. J Virol"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0230","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","article-title":"The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3","volume":"78","author":"Sirena","year":"2004","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0235","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1128\/jvi.68.10.6811-6814.1994","article-title":"Multiple adenovirus serotypes use alpha v integrins for infection","volume":"68","author":"Mathias","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.smim.2020.101430_bib0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2016.06.001","article-title":"Viral vectors as vaccine carriers","volume":"21","author":"Ertl","year":"2016","journal-title":"Curr. Opin. Virol."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0245","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","article-title":"Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines","volume":"110","author":"Tatsis","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.smim.2020.101430_bib0250","doi-asserted-by":"crossref","first-page":"7392","DOI":"10.1128\/JVI.78.14.7392-7399.2004","article-title":"Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes","volume":"78","author":"Reyes-Sandoval","year":"2004","journal-title":"J. Virol."},{"issue":"115","key":"10.1016\/j.smim.2020.101430_bib0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002925","article-title":"Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species","volume":"4","author":"Colloca","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0260","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.3201\/eid1210.060078","article-title":"Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa","volume":"12","author":"Xiang","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0265","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/infdis\/jis285","article-title":"Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials","volume":"205","author":"Stephenson","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0270","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/104303404322886147","article-title":"Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines","volume":"15","author":"Aste-Amezaga","year":"2004","journal-title":"Hum. Gene Ther."},{"issue":"50","key":"10.1016\/j.smim.2020.101430_bib0275","doi-asserted-by":"crossref","first-page":"E3503","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0280","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1086\/509258","article-title":"Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector","volume":"194","author":"Catanzaro","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0285","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1086\/587993","article-title":"Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag\/pol\/nef vaccine in healthy adults","volume":"46","author":"Priddy","year":"2008","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.smim.2020.101430_bib0290","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nm.1991","article-title":"Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans","volume":"15","author":"O\u2019Brien","year":"2009","journal-title":"Nat. Med."},{"issue":"9653","key":"10.1016\/j.smim.2020.101430_bib0295","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0300","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/mt.2015.194","article-title":"Development of novel adenoviral vectors to overcome challenges observed with HAdV-5-based constructs","volume":"24","author":"Alonso-Padilla","year":"2016","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0305","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jgm.1530","article-title":"Creation of a panel of vectors based on ape adenovirus isolates","volume":"13","author":"Roy","year":"2011","journal-title":"J. Gene Med."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0310","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jmv.23546","article-title":"Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults","volume":"85","author":"Zhang","year":"2013","journal-title":"J. Med. Virol."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0315","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.4049\/jimmunol.1202861","article-title":"Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization","volume":"190","author":"Quinn","year":"2013","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000503","article-title":"Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates","volume":"5","author":"Roy","year":"2009","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0325","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1128\/JVI.02950-14","article-title":"Construction and evaluation of novel rhesus monkey adenovirus vaccine vectors","volume":"89","author":"Abbink","year":"2015","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0330","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/mt.2013.142","article-title":"Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation","volume":"22","author":"Johnson","year":"2014","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0335","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/sj.mt.6300078","article-title":"A CD46-binding chimpanzee adenovirus vector as a vaccine carrier","volume":"15","author":"Tatsis","year":"2007","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0340","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.mt.6300024","article-title":"Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector","volume":"15","author":"Hensley","year":"2007","journal-title":"Mol. Ther."},{"issue":"35","key":"10.1016\/j.smim.2020.101430_bib0345","doi-asserted-by":"crossref","first-page":"5691","DOI":"10.1016\/j.vaccine.2010.06.050","article-title":"Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vaccine vector based on rare human serotype 28","volume":"28","author":"Kahl","year":"2010","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.smim.2020.101430_bib0350","doi-asserted-by":"crossref","first-page":"9590","DOI":"10.1128\/JVI.00740-12","article-title":"Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys","volume":"86","author":"Teigler","year":"2012","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0355","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1172\/JCI78280","article-title":"Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling","volume":"125","author":"Quinn","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.smim.2020.101430_bib0360","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","article-title":"Protection of non-human primates against rabies with an adenovirus recombinant vaccine","volume":"450-451","author":"Xiang","year":"2014","journal-title":"Virology"},{"issue":"300","key":"10.1016\/j.smim.2020.101430_bib0365","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5757","article-title":"Efficacy of a virus-vectored vaccine against human and bovine respiratory syncytial virus infections","volume":"7","author":"Taylor","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.smim.2020.101430_bib0370","doi-asserted-by":"crossref","first-page":"eaba8399","DOI":"10.1126\/sciadv.aba8399","article-title":"A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques","volume":"6","author":"van Doremalen","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0375","doi-asserted-by":"crossref","first-page":"16292","DOI":"10.1038\/s41598-019-52730-4","article-title":"Humoral immunogenicity and efficacy of a single dose of ChAdOx1 MERS vaccine candidate in dromedary camels","volume":"9","author":"Alharbi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.smim.2020.101430_bib0380","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"van Doremalen","year":"2020","journal-title":"bioRxivorg"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0385","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0390","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O\u2019Hara","year":"2012","journal-title":"J. Infect. Dis."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0400","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/14760584.2017.1394842","article-title":"Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane","volume":"16","author":"Vitelli","year":"2017","journal-title":"Expert Rev. Vaccines"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005527","article-title":"A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: first-in-human trial of ChAd63-KH","volume":"11","author":"Osman","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib0410","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1473-3099(20)30160-2","article-title":"Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial","volume":"20","author":"Folegatti","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0415","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/cid\/ciz653","volume":"70","author":"Cicconi","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0420","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.jinf.2019.02.003","article-title":"Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults","volume":"78","author":"Green","year":"2019","journal-title":"J. Infect."},{"key":"10.1016\/j.smim.2020.101430_bib0425","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ebiom.2018.02.011","article-title":"Heterologous two-dose vaccination with simian adenovirus and poxvirus vectors elicits long-lasting cellular immunity to influenza virus a in healthy adults","volume":"29","author":"Coughlan","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.smim.2020.101430_bib0430","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.virusres.2016.10.010","article-title":"The family Rhabdoviridae: mono- and bipartite negative-sense RNA viruses with diverse genome organization and common evolutionary origins","volume":"227","author":"Dietzgen","year":"2017","journal-title":"Virus Res."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0435","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1038\/mt.2009.154","article-title":"Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus","volume":"17","author":"Bridle","year":"2009","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0440","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1073\/pnas.92.10.4477","article-title":"Recombinant vesicular stomatitis viruses from DNA","volume":"92","author":"Lawson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0445","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jviromet.2006.02.006","article-title":"An efficient helper-virus-free method for rescue of recombinant paramyxoviruses and rhadoviruses from a cell line suitable for vaccine development","volume":"135","author":"Witko","year":"2006","journal-title":"J. Virol. Methods"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0455","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1080\/02648725.2018.1474320","article-title":"Rhabdoviruses as vaccine platforms for infectious disease and cancer","volume":"34","author":"Zemp","year":"2018","journal-title":"Biotechnol. Genet. Eng. Rev."},{"issue":"Suppl 3","key":"10.1016\/j.smim.2020.101430_bib0460","doi-asserted-by":"crossref","first-page":"S1075","DOI":"10.1093\/infdis\/jir349","article-title":"Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections","volume":"204","author":"Geisbert","year":"2011","journal-title":"J. Infect. Dis."},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0465","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"issue":"6249","key":"10.1016\/j.smim.2020.101430_bib0470","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1126\/science.aab3920","article-title":"EBOLA VACCINE. VSV-EBOV rapidly protects macaques against infection with the 2014\/15 Ebola virus outbreak strain","volume":"349","author":"Marzi","year":"2015","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0475","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PLoS Pathog."},{"issue":"17","key":"10.1016\/j.smim.2020.101430_bib0480","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.smim.2020.101430_bib0485","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0490","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)-Specific humoral and cellular immune responses following VSV-Ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"7549","key":"10.1016\/j.smim.2020.101430_bib0495","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/nature14428","article-title":"Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus","volume":"520","author":"Mire","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0500","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","article-title":"Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Clarke","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0505","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv082","article-title":"First-in-Human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency Virus-1 gag vaccine (HVTN 090)","volume":"2","author":"Fuchs","year":"2015","journal-title":"Open Forum Infect. Dis."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0510","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3201\/eid2102.141649","article-title":"Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses","volume":"21","author":"Marzi","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.smim.2020.101430_bib0515","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.coviro.2017.05.004","article-title":"Structure and organization of paramyxovirus particles","volume":"24","author":"Cox","year":"2017","journal-title":"Curr. Opin. Virol."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0520","doi-asserted-by":"crossref","DOI":"10.3390\/v8110308","article-title":"Host-pathogen interactions in measles virus replication and anti-viral immunity","volume":"8","author":"Jiang","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.smim.2020.101430_bib0525","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.virol.2015.01.029","article-title":"Reverse genetics of Mononegavirales: how they work, new vaccines, and new cancer therapeutics","volume":"479-480","author":"Pfaller","year":"2015","journal-title":"Virology"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0530","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1089\/vim.2017.0143","article-title":"Measles vaccine","volume":"31","author":"Griffin","year":"2018","journal-title":"Viral Immunol."},{"issue":"RR-04","key":"10.1016\/j.smim.2020.101430_bib0535","first-page":"1","article-title":"Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"McLean","year":"2013","journal-title":"MMWR Recomm. Rep."},{"issue":"24","key":"10.1016\/j.smim.2020.101430_bib0540","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/j.vaccine.2009.02.066","article-title":"Development of measles vaccines in Japan","volume":"27","author":"Ueda","year":"2009","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0545","first-page":"571","article-title":"The status of measles after five years of mass vaccination in the USSR","volume":"49","author":"Burgasov","year":"1973","journal-title":"Bull. World Health Organ."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0550","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1128\/JVI.02924-14","article-title":"Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates","volume":"89","author":"Rennick","year":"2015","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0555","doi-asserted-by":"crossref","first-page":"7420","DOI":"10.1128\/JVI.72.9.7420-7427.1998","article-title":"Measles virus spread and pathogenesis in genetically modified mice","volume":"72","author":"Mrkic","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0560","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1128\/JVI.78.1.146-157.2004","article-title":"A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV","volume":"78","author":"Lorin","year":"2004","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0565","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050397","article-title":"Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine","volume":"7","author":"Stebbings","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0570","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1371\/journal.pntd.0000096","article-title":"Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus","volume":"1","author":"Brandler","year":"2007","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0575","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1086\/426824","article-title":"Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis","volume":"191","author":"Despres","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"22","key":"10.1016\/j.smim.2020.101430_bib0580","doi-asserted-by":"crossref","first-page":"11654","DOI":"10.1128\/JVI.01815-15","article-title":"A highly immunogenic and protective middle east respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform","volume":"89","author":"Malczyk","year":"2015","journal-title":"J. Virol."},{"issue":"36","key":"10.1016\/j.smim.2020.101430_bib0585","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1016\/j.vaccine.2013.05.086","article-title":"A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus","volume":"31","author":"Brandler","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0590","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/infdis\/jiz202","article-title":"Immunogenicity and efficacy of a measles virus-vectored chikungunya vaccine in nonhuman Primates","volume":"220","author":"Rossi","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0595","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1473-3099(15)70043-5","article-title":"Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial","volume":"15","author":"Ramsauer","year":"2015","journal-title":"Lancet Infect. Dis."},{"issue":"10165","key":"10.1016\/j.smim.2020.101430_bib0600","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0605","doi-asserted-by":"crossref","first-page":"6393","DOI":"10.1128\/JVI.76.12.6393-6397.2002","article-title":"Identification of the lymphocytic choriomeningitis virus (LCMV) proteins required to rescue LCMV RNA analogs into LCMV-like particles","volume":"76","author":"Lee","year":"2002","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0610","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005276","article-title":"Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection","volume":"11","author":"Sommerstein","year":"2015","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0615","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0620","doi-asserted-by":"crossref","DOI":"10.1128\/CVI.00300-16","article-title":"Additive protection against congenital cytomegalovirus conferred by combined glycoprotein B\/pp65 vaccination using a lymphocytic choriomeningitis virus vector","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.smim.2020.101430_bib0625","doi-asserted-by":"crossref","first-page":"15327","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8(+) T cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0630","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vaccine.2016.11.063","article-title":"Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens","volume":"35","author":"Penaloza MacMaster","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.smim.2020.101430_bib0635","article-title":"A randomized dose-escalating phase I trial of a replication-deficient lymphocytic choriomeningitis virus vector-based vaccine against human cytomegalovirus","author":"Schwendinger","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.06.028","article-title":"An unbiased screen for human cytomegalovirus identifies Neuropilin-2 as a central viral receptor","volume":"174","author":"Martinez-Martin","year":"2018","journal-title":"Cell"},{"issue":"14","key":"10.1016\/j.smim.2020.101430_bib0645","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1073\/pnas.1814850116","article-title":"OR14I1 is a receptor for the human cytomegalovirus pentameric complex and defines viral epithelial cell tropism","volume":"116","author":"E, X","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0650","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nri.2016.38","article-title":"T cell responses to cytomegalovirus","volume":"16","author":"Klenerman","year":"2016","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0655","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0660","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02128-16","article-title":"Human cytomegalovirus (HCMV)-Specific CD4(+) t cells are polyfunctional and can respond to HCMV-Infected dendritic cells in vitro","volume":"91","author":"Jackson","year":"2017","journal-title":"J. Virol."},{"issue":"18","key":"10.1016\/j.smim.2020.101430_bib0665","doi-asserted-by":"crossref","first-page":"10894","DOI":"10.1128\/JVI.01477-14","article-title":"Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells","volume":"88","author":"Jackson","year":"2014","journal-title":"J. Virol."},{"issue":"Pt 2","key":"10.1016\/j.smim.2020.101430_bib0670","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1099\/vir.0.070441-0","article-title":"Differential kinetics of human cytomegalovirus load and antibody responses in primary infection of the immunocompetent and immunocompromised host","volume":"96","author":"Gerna","year":"2015","journal-title":"J. Gen. Virol."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0675","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nm.1935","article-title":"Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge","volume":"15","author":"Hansen","year":"2009","journal-title":"Nat. Med."},{"issue":"7348","key":"10.1016\/j.smim.2020.101430_bib0680","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature10003","article-title":"Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine","volume":"473","author":"Hansen","year":"2011","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.smim.2020.101430_bib0685","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Boppana","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0690","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.4473","article-title":"Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine","volume":"24","author":"Hansen","year":"2018","journal-title":"Nat. Med."},{"issue":"6274","key":"10.1016\/j.smim.2020.101430_bib0695","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1126\/science.aac9475","article-title":"Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E","volume":"351","author":"Hansen","year":"2016","journal-title":"Science"},{"issue":"6135","key":"10.1016\/j.smim.2020.101430_bib0700","doi-asserted-by":"crossref","DOI":"10.1126\/science.1237874","article-title":"Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms","volume":"340","author":"Hansen","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.smim.2020.101430_bib0705","first-page":"63","article-title":"Cytomegalovirus cell tropism","volume":"325","author":"Sinzger","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1-2","key":"10.1016\/j.smim.2020.101430_bib0710","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.virol.2013.08.026","article-title":"Coding potential of UL\/b\u2019 from the initial source of rhesus cytomegalovirus Strain 68-1","volume":"447","author":"Gill","year":"2013","journal-title":"Virology"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0715","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/infdis\/jiw365","article-title":"A phase 1 study of 4 live, recombinant human cytomegalovirus Towne\/Toledo chimera vaccines in cytomegalovirus-seronegative men","volume":"214","author":"Adler","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"501","key":"10.1016\/j.smim.2020.101430_bib0720","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2607","article-title":"A live-attenuated RhCMV\/SIV vaccine shows long-term efficacy against heterologous SIV challenge","volume":"11","author":"Hansen","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0725","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.vaccine.2015.11.062","article-title":"Prime-boost vaccine strategy against viral infections: mechanisms and benefits","volume":"34","author":"Kardani","year":"2016","journal-title":"Vaccine"},{"issue":"20","key":"10.1016\/j.smim.2020.101430_bib0730","doi-asserted-by":"crossref","first-page":"11434","DOI":"10.1128\/JVI.78.20.11434-11438.2004","article-title":"Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors","volume":"78","author":"Casimiro","year":"2004","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0735","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.smim.2020.101430_bib0740","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat. Commun."},{"issue":"286","key":"10.1016\/j.smim.2020.101430_bib0745","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0750","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral vector malaria vaccines induce high-level t cell and antibody responses in west african children and infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0755","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response","volume":"183","author":"Akondy","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.smim.2020.101430_bib0760","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3389\/fimmu.2018.03175","article-title":"A novel vaccine strategy employing serologically different chimpanzee adenoviral vectors for the prevention of HIV-1 and HCV coinfection","volume":"9","author":"Hartnell","year":"2018","journal-title":"Front. Immunol."},{"issue":"300","key":"10.1016\/j.smim.2020.101430_bib0765","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5745","article-title":"Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults","volume":"7","author":"Green","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.smim.2020.101430_bib0770","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1056\/NEJMoa1411627","article-title":"A monovalent chimpanzee adenovirus ebola vaccine boosted with MVA","volume":"374","author":"Ewer","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0775","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1473-3099(15)00362-X","volume":"16","author":"Tapia","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"15","key":"10.1016\/j.smim.2020.101430_bib0780","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2016.4218","article-title":"Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia ankara-vectored ebola vaccines: a randomized clinical trial","volume":"315","author":"Milligan","year":"2016","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0785","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jama.2016.20644","article-title":"Immune responses to novel adenovirus type 26 and modified vaccinia virus ankara-vectored ebola vaccines at 1 year","volume":"317","author":"Winslow","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0790","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/infdis\/jiz070","article-title":"Safety and immunogenicity of a 2-Dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo ebola vaccines: 12-Month data from a phase 1 randomized clinical trial in Uganda and Tanzania","volume":"220","author":"Anywaine","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0795","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/infdis\/jiz071","article-title":"Safety and immunogenicity of a 2-Dose heterologous vaccine regimen with Ad26.ZEBOV and MVA-BN-Filo ebola vaccines: 12-Month data from a phase 1 randomized clinical trial in Nairobi","volume":"220","author":"Mutua","year":"2019","journal-title":"Kenya. J Infect Dis"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0800","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/21645515.2016.1238535","article-title":"Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: an open phase I\/II trial in healthy adults in Russia","volume":"13","author":"Dolzhikova","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.smim.2020.101430_bib0805","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New vaccine technologies to combat outbreak situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0810","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.exppara.2009.02.010","article-title":"Plasmodium: mammalian codon optimization of malaria plasmid DNA vaccines enhances antibody responses but not T cell responses nor protective immunity","volume":"122","author":"Dobano","year":"2009","journal-title":"Exp. Parasitol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0815","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1389202916666141223220551","article-title":"Genetics and vaccines in the era of personalized medicine","volume":"16","author":"Castiblanco","year":"2015","journal-title":"Curr. Genomics"},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib0820","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1080\/21645515.2017.1383575","article-title":"Chimpanzee adenoviral vectors as vaccines for outbreak pathogens","volume":"13","author":"Ewer","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib0825","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040385","article-title":"A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity","volume":"7","author":"Dicks","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0830","doi-asserted-by":"crossref","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0835","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/jat.3941","article-title":"Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine","volume":"40","author":"Planty","year":"2020","journal-title":"J. Appl. Toxicol."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib0840","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/15376510802312464","volume":"5","author":"Sheets","year":"2008","journal-title":"J. Immunotoxicol."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib0845","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008459","article-title":"A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C","volume":"14","author":"Napolitano","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib0850","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0855","doi-asserted-by":"crossref","DOI":"10.3390\/toxins12040241","article-title":"Talkin\u2019 toxins: from Coley\u2019s to modern Cancer immunotherapy","volume":"12","author":"Carlson","year":"2020","journal-title":"Toxins (Basel)"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib0860","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0865","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S1470-2045(16)00099-1","article-title":"Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Vansteenkiste","year":"2016","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0870","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0875","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0880","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib0885","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","article-title":"Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial","volume":"19","author":"Hodi","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0890","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s40425-018-0349-3","article-title":"Current landscape and future of dual anti-CTLA4 and PD-1\/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)","volume":"6","author":"Chae","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"26","key":"10.1016\/j.smim.2020.101430_bib0895","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib0900","doi-asserted-by":"crossref","first-page":"8706","DOI":"10.18632\/oncotarget.24283","article-title":"Analysis of response rate with ANTI PD1\/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials","volume":"9","author":"Carretero-Gonzalez","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0905","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to Cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0910","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: a review of current evidence","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"5038","key":"10.1016\/j.smim.2020.101430_bib0915","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0920","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1128\/CVI.00286-10","article-title":"Translating tumor antigens into cancer vaccines","volume":"18","author":"Buonaguro","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"issue":"6230","key":"10.1016\/j.smim.2020.101430_bib0925","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib0930","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/nm.4051","article-title":"Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients","volume":"22","author":"Gros","year":"2016","journal-title":"Nat. Med."},{"issue":"7385","key":"10.1016\/j.smim.2020.101430_bib0935","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0940","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-11-3722","article-title":"Exploiting the mutanome for tumor vaccination","volume":"72","author":"Castle","year":"2012","journal-title":"Cancer Res."},{"issue":"7528","key":"10.1016\/j.smim.2020.101430_bib0945","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.smim.2020.101430_bib0950","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"7549","key":"10.1016\/j.smim.2020.101430_bib0955","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.smim.2020.101430_bib0960","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"7662","key":"10.1016\/j.smim.2020.101430_bib0965","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib0970","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J."},{"issue":"1-2","key":"10.1016\/j.smim.2020.101430_bib0975","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2013.05.041","article-title":"Adenoviruses isolated from wild gorillas are closely related to human species C viruses","volume":"444","author":"Duncan","year":"2013","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib0980","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","article-title":"Translational implications of tumor heterogeneity","volume":"21","author":"Jamal-Hanjani","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7749","key":"10.1016\/j.smim.2020.101430_bib0985","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib0990","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","article-title":"Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade","volume":"10","author":"D\u2019Alise","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib0995","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nbt.3800","article-title":"The problem with neoantigen prediction","volume":"35","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.smim.2020.101430_bib1000","doi-asserted-by":"crossref","DOI":"10.1158\/0008-5472.CAN-20-1072","article-title":"A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability","author":"Leoni","year":"2020","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib1005","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","article-title":"Cellular vaccine approaches","volume":"16","author":"Le","year":"2010","journal-title":"Cancer J."},{"key":"10.1016\/j.smim.2020.101430_bib1010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41541-019-0103-y","article-title":"Turning the corner on therapeutic cancer vaccines","volume":"4","author":"Hollingsworth","year":"2019","journal-title":"Npj Vaccines"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib1015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/sj.gt.3301885","article-title":"ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties","volume":"10","author":"Liu","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2020.101430_bib1020","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3389\/fonc.2020.01786","article-title":"The oncolytic virus in Cancer diagnosis and treatment","volume":"10","author":"Cao","year":"2020","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1025","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s40425-019-0682-1","article-title":"Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1","volume":"7","author":"Thomas","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.smim.2020.101430_bib1030","doi-asserted-by":"crossref","first-page":"15001","DOI":"10.1038\/mto.2015.1","article-title":"Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein","volume":"2","author":"van Erp","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"issue":"8","key":"10.1016\/j.smim.2020.101430_bib1035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007209","article-title":"A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors","volume":"14","author":"Leoni","year":"2018","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1040","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1158\/1535-7163.MCT-20-0134","article-title":"Retargeted and stealth-modified oncolytic measles viruses for systemic Cancer therapy in measles immune patients","volume":"19","author":"Bah","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.smim.2020.101430_bib1045","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.omtm.2020.03.028","article-title":"Preclinical toxicology of rQNestin34.5v.2: an oncolytic herpes virus with transcriptional regulation of the ICP34.5 neurovirulence gene","volume":"17","author":"Chiocca","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1050","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1055","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/mt.2014.177","article-title":"Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV","volume":"23","author":"Mazzacurati","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1060","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/s41598-020-61275-w","article-title":"Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis","volume":"10","author":"Sasso","year":"2020","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib1065","doi-asserted-by":"crossref","first-page":"28658","DOI":"10.18632\/oncotarget.8637","article-title":"Tumour-specific triple-regulated oncolytic herpes virus to target glioma","volume":"7","author":"Delwar","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib1070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: how \"lytic\" must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1075","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1080","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1085","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000337","article-title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","volume":"8","author":"Galluzzi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1090","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.01.051","article-title":"SnapShot: Cancer Immunotherapy with Oncolytic Viruses","volume":"176","author":"Gujar","year":"2019","journal-title":"Cell"},{"issue":"7637","key":"10.1016\/j.smim.2020.101430_bib1095","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.smim.2020.101430_bib1100","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ebiom.2018.04.020","article-title":"Lighting a fire in the tumor microenvironment using oncolytic immunotherapy","volume":"31","author":"Achard","year":"2018","journal-title":"EBioMedicine"},{"issue":"13","key":"10.1016\/j.smim.2020.101430_bib1105","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with Talimogene Laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1115","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann. Surg. Oncol."},{"issue":"41","key":"10.1016\/j.smim.2020.101430_bib1120","doi-asserted-by":"crossref","first-page":"71249","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41419-020-2567-0","article-title":"Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment","volume":"11","author":"Serpico","year":"2020","journal-title":"Cell Death Dis."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nri3845","article-title":"Type I interferons in anticancer immunity","volume":"15","author":"Zitvogel","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"408","key":"10.1016\/j.smim.2020.101430_bib1135","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan4220","article-title":"Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs","volume":"9","author":"Brown","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.chom.2016.01.010","article-title":"The cGAS-STING defense pathway and its counteraction by viruses","volume":"19","author":"Ma","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"3\u20134","key":"10.1016\/j.smim.2020.101430_bib1145","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00430-019-00582-0","article-title":"Coevolution pays off: herpesviruses have the license to escape the DNA sensing pathway","volume":"208","author":"Stempel","year":"2019","journal-title":"Med. Microbiol. Immunol."},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib1150","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00879-18","article-title":"Engineered oncolytic poliovirus PVSRIPO subverts MDA5-Dependent innate immune responses in Cancer cells","volume":"92","author":"Walton","year":"2018","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1155","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2613.2001.00204.x","article-title":"Viral escape mechanisms--escapology taught by viruses","volume":"82","author":"Lucas","year":"2001","journal-title":"Int. J. Exp. Pathol."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1591875","article-title":"Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma","volume":"8","author":"Bommareddy","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.smim.2020.101430_bib1165","doi-asserted-by":"crossref","first-page":"14006","DOI":"10.1038\/mto.2014.6","article-title":"Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy","volume":"1","author":"Vaha-Koskela","year":"2015","journal-title":"Mol. Ther. Oncolytics"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1170","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.gt.3301003","article-title":"Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice","volume":"6","author":"Chahlavi","year":"1999","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib1175","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as antigen-agnostic Cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib1180","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.it.2017.11.006","article-title":"Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies","volume":"39","author":"Gujar","year":"2018","journal-title":"Trends Immunol."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1190","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/2326-6066.CIR-18-0309","article-title":"Antibody-neutralized reovirus is effective in oncolytic virotherapy","volume":"6","author":"Berkeley","year":"2018","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"Tirado","year":"2003","journal-title":"Viral Immunol."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib1200","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib1205","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1158\/1078-0432.CCR-18-4022","article-title":"Phase I trial of an ICAM-1-Targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder Cancer","volume":"25","author":"Annels","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1210","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910375","article-title":"Repurposing the yellow fever vaccine for intratumoral immunotherapy","volume":"12","author":"Aznar","year":"2020","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1215","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","article-title":"Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune-checkpoint blockade","volume":"25","author":"Chon","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib1220","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14712598.2020.1729351","article-title":"Combination therapy with oncolytic viruses and immune checkpoint inhibitors","volume":"20","author":"Chiu","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"issue":"20","key":"10.1016\/j.smim.2020.101430_bib1225","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1158\/1078-0432.CCR-17-0681","article-title":"Local delivery of OncoVEX(mGM-CSF) generates systemic antitumor immune responses enhanced by cytotoxic T-Lymphocyte-Associated protein blockade","volume":"23","author":"Moesta","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"226","key":"10.1016\/j.smim.2020.101430_bib1230","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1235","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/mt.2015.115","article-title":"Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses","volume":"23","author":"Woller","year":"2015","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1240","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","article-title":"An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101430_bib1245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.omto.2019.04.003","article-title":"Oncolytic viruses and immune checkpoint inhibition: the best of both worlds","volume":"13","author":"Sivanandam","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2020.101430_bib1250","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.copbio.2019.11.016","article-title":"Design and application of oncolytic viruses for cancer immunotherapy","volume":"65","author":"Ylosmaki","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"issue":"17","key":"10.1016\/j.smim.2020.101430_bib1255","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of Talimogene Laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1260","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1634\/theoncologist.2019-0438","article-title":"Intratumoral immunotherapy-update 2019","volume":"25","author":"Hamid","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.smim.2020.101430_bib1265","first-page":"1","article-title":"Recent advances of oncolytic virus in cancer therapy","author":"Mondal","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.smim.2020.101430_bib1270","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for Cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1275","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/2159-8290.CD-RW2020-018","article-title":"Talimogene laherparepvec plus pembrolizumab is effective in sarcomas","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"issue":"422","key":"10.1016\/j.smim.2020.101430_bib1280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1285","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00262-020-02487-x","article-title":"Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB-IV M1c melanoma patients","volume":"69","author":"Frohlich","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1290","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1158\/1078-0432.CCR-16-0477","article-title":"The efficacy of oncolytic adenovirus is mediated by T-cell responses against virus and tumor in syrian Hamster model","volume":"23","author":"Li","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1295","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/s41598-018-38385-7","article-title":"Pre-surgical neoadjuvant oncolytic virotherapy confers protection against rechallenge in a murine model of breast cancer","volume":"9","author":"Martin","year":"2019","journal-title":"Sci. Rep."},{"issue":"422","key":"10.1016\/j.smim.2020.101430_bib1300","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao1641","article-title":"Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy","volume":"10","author":"Bourgeois-Daigneault","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"Pt A","key":"10.1016\/j.smim.2020.101430_bib1305","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","article-title":"Progress and problems with the use of suicide genes for targeted cancer therapy","volume":"99","author":"Karjoo","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1310","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/aps.2009.33","article-title":"Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase\/ganciclovir in hepatic carcinoma animal models","volume":"30","author":"Zheng","year":"2009","journal-title":"Acta Pharmacol. Sin."},{"issue":"14","key":"10.1016\/j.smim.2020.101430_bib1315","first-page":"5447","article-title":"Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil","volume":"61","author":"Nakamura","year":"2001","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib1320","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s10517-016-3517-9","article-title":"Expression of therapeutic gene FCU1 sensitizes pancreatic Cancer cells to 5-Fluorocytosine and enhances the cytotoxic effect of 5-Fluorouracil","volume":"161","author":"Kopantsev","year":"2016","journal-title":"Bull. Exp. Biol. Med."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1325","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.ymthe.2005.03.017","article-title":"Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma","volume":"12","author":"Tai","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.smim.2020.101430_bib1330","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2019.03.005","article-title":"The enhanced tumor specificity of TG6002, an armed oncolytic vaccinia virus deleted in two genes involved in nucleotide metabolism","volume":"14","author":"Foloppe","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1335","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/neuonc\/nox037","article-title":"Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model","volume":"19","author":"Mitchell","year":"2017","journal-title":"Neuro Oncol"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1340","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/neuonc\/noy075","article-title":"Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC","volume":"20","author":"Cloughesy","year":"2018","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1345","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1089\/hum.2011.128","article-title":"Oncolytic measles virus encoding thyroidal sodium iodide symporter for squamous cell cancer of the head and neck radiovirotherapy","volume":"23","author":"Li","year":"2012","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1350","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.smim.2020.101430_bib1355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.omto.2019.09.006","article-title":"Syncytia formation in oncolytic virotherapy","volume":"15","author":"Burton","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1360","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/archoto.2009.214","article-title":"Oncolysis using herpes simplex virus type 1 engineered to express cytosine deaminase and a fusogenic glycoprotein for head and neck squamous cell carcinoma","volume":"136","author":"Price","year":"2010","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1365","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10070216","article-title":"Fusogenic viruses in oncolytic immunotherapy","volume":"10","author":"Krabbe","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.smim.2020.101430_bib1370","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.omto.2017.08.001","article-title":"Reovirus FAST protein enhances vesicular stomatitis virus oncolytic virotherapy in primary and metastatic tumor models","volume":"6","author":"Le Boeuf","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1375","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/gt.2011.184","article-title":"GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution","volume":"19","author":"Guedan","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2020.101430_bib1380","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/1743-422X-8-294","article-title":"A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma","volume":"8","author":"Takaoka","year":"2011","journal-title":"Virol. J."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1385","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.ymthe.2006.02.007","article-title":"A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus","volume":"13","author":"Fu","year":"2006","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1390","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1158\/0008-5472.CAN-13-3696","article-title":"Releasing pressure in tumors: what do we know so far and where do we go from here? A review","volume":"74","author":"Ariffin","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1395","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.smim.2020.101430_bib1400","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.omto.2019.10.005","article-title":"GBM-targeted oHSV armed with matrix metalloproteinase 9 enhances anti-tumor activity and animal survival","volume":"15","author":"Sette","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib1405","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1158\/1078-0432.CCR-15-1899","article-title":"The oncolytic adenovirus VCN-01 as therapeutic approach against pediatric osteosarcoma","volume":"22","author":"Martinez-Velez","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1410","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147211","article-title":"Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01","volume":"11","author":"Vera","year":"2016","journal-title":"PLoS One"},{"issue":"476","key":"10.1016\/j.smim.2020.101430_bib1415","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat9321","article-title":"Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01","volume":"11","author":"Pascual-Pasto","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"24","key":"10.1016\/j.smim.2020.101430_bib1420","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets Cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1425","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.3390\/v7072811","article-title":"Preclinical testing oncolytic vaccinia virus strain GLV-5b451 expressing an Anti-VEGF single-chain antibody for canine Cancer therapy","volume":"7","author":"Adelfinger","year":"2015","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1430","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/mt.2009.232","article-title":"Enhanced antitumor efficacy of vasculostatin (Vstat120) expressing oncolytic HSV-1","volume":"18","author":"Hardcastle","year":"2010","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1435","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s40425-019-0641-x","article-title":"Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer","volume":"7","author":"McGray","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1440","doi-asserted-by":"crossref","first-page":"16892","DOI":"10.1038\/s41598-017-16928-8","article-title":"Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles","volume":"7","author":"Hutzler","year":"2017","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1445","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/mt.2013.249","article-title":"Maraba virus as a potent oncolytic vaccine vector","volume":"22","author":"Pol","year":"2014","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1450","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/2326-6066.CIR-17-0102","article-title":"Customized viral immunotherapy for HPV-Associated Cancer","volume":"5","author":"Atherton","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1455","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1512329","article-title":"Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials","volume":"8","author":"Pol","year":"2019","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1460","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/omcr\/omz105","article-title":"Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients","volume":"2019","author":"Bouvet","year":"2019","journal-title":"Oxf. Med. Case Reports"},{"issue":"4","key":"10.1016\/j.smim.2020.101430_bib1465","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1105429","article-title":"Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma","volume":"5","author":"Capasso","year":"2016","journal-title":"Oncoimmunology"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib1470","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1016\/j.ymthe.2018.06.008","article-title":"Personalized Cancer vaccine platform for clinically relevant oncolytic enveloped viruses","volume":"26","author":"Ylosmaki","year":"2018","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.smim.2020.101430_bib1475","article-title":"Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors","volume":"7","author":"Feola","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1480","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41416-018-0328-y","article-title":"Cytokines in clinical cancer immunotherapy","volume":"120","author":"Berraondo","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.smim.2020.101430_bib1485","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2018.03.006","article-title":"Armed oncolytic viruses: a kick-start for anti-tumor immunity","volume":"41","author":"de Graaf","year":"2018","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.smim.2020.101430_bib1490","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2019.03.001","article-title":"Oncolytic virus-based cytokine expression to improve immune activity in brain and solid tumors","volume":"13","author":"Pearl","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.smim.2020.101430_bib1495","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/mto.2016.1","article-title":"Oncolytic vesicular stomatitis virus expressing interferon-gamma has enhanced therapeutic activity","volume":"3","author":"Bourgeois-Daigneault","year":"2016","journal-title":"Mol. Ther. Oncolytics"},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1500","article-title":"HSV as a platform for the generation of retargeted, armed, and reporter-expressing oncolytic","volume":"10","author":"Menotti","year":"2018","journal-title":"Viruses. Viruses"},{"issue":"23","key":"10.1016\/j.smim.2020.101430_bib1505","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1038\/s41388-019-0737-2","article-title":"Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model","volume":"38","author":"Alessandrini","year":"2019","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1510","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"issue":"185","key":"10.1016\/j.smim.2020.101430_bib1515","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005361","article-title":"Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans","volume":"5","author":"Kim","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.smim.2020.101430_bib1520","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40425-016-0121-5","article-title":"Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers","volume":"4","author":"Ranki","year":"2016","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1525","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.urolonc.2017.07.005","article-title":"An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results","volume":"36","author":"Packiam","year":"2018","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.smim.2020.101430_bib1530","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-4939-2727-2_19","article-title":"A phase 2, open-label, randomized study of pexa-vec (JX-594) administered by intratumoral injection in patients with unresectable primary hepatocellular carcinoma","volume":"1317","author":"Breitbach","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1535","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000188","article-title":"Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity","volume":"8","author":"Santos","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1540","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/humc.2016.031","article-title":"Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with Recurrent\/Progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma","volume":"27","author":"Patel","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"issue":"12","key":"10.1016\/j.smim.2020.101430_bib1545","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/gt.2013.40","article-title":"Efficacy of oncolytic adenovirus expressing suicide genes and interleukin-12 in preclinical model of prostate cancer","volume":"20","author":"Freytag","year":"2013","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.smim.2020.101430_bib1550","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060171","article-title":"Tune up in situ autovaccination against solid tumors with oncolytic viruses","volume":"10","author":"Nguyen","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1555","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020400","article-title":"Oncolytic virus encoding a master pro-inflammatory cytokine interleukin 12 in Cancer immunotherapy","volume":"9","author":"Nguyen","year":"2020","journal-title":"Cells"},{"issue":"9","key":"10.1016\/j.smim.2020.101430_bib1560","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1158\/1078-0432.CCR-18-3626","article-title":"Synergistic combination of oncolytic virotherapy and immunotherapy for glioma","volume":"26","author":"Tang","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1565","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-Armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1570","doi-asserted-by":"crossref","DOI":"10.3390\/v11100914","article-title":"Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists","volume":"11","author":"Backhaus","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1575","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-018-06954-z","article-title":"Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.smim.2020.101430_bib1580","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.omto.2020.04.006","article-title":"In situ therapeutic Cancer vaccination with an oncolytic virus expressing membrane-tethered IL-2","volume":"17","author":"Liu","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1585","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1590","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.smim.2020.101430_bib1595","first-page":"1060","article-title":"Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies","volume":"10","author":"Sasso","year":"2018","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1600","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1080\/19420862.2018.1463945","article-title":"A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells","volume":"10","author":"Sasso","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.smim.2020.101430_bib1605","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/703213","article-title":"One-step recovery of scFv clones from high-throughput sequencing-based screening of phage display libraries challenged to cells expressing native Claudin-1","volume":"2015","author":"Sasso","year":"2015","journal-title":"Biomed Res. Int."},{"issue":"23","key":"10.1016\/j.smim.2020.101430_bib1610","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.18632\/oncotarget.26785","article-title":"PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models","volume":"10","author":"Mitchell","year":"2019","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1615","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1158\/0008-5472.CAN-16-1638","article-title":"Tumor-localized secretion of soluble PD1 enhances oncolytic virotherapy","volume":"77","author":"Bartee","year":"2017","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1620","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-19-0628","article-title":"Intratumoral delivery of a PD-1-Blocking scFv encoded in oncolytic HSV-1 promotes antitumor immunity and synergizes with TIGIT blockade","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.smim.2020.101430_bib1625","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.omto.2019.10.003","article-title":"Enhanced therapeutic efficacy of a novel oncolytic herpes simplex virus type 2 encoding an antibody against programmed cell death 1","volume":"15","author":"Zhu","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1630","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.smim.2020.101430_bib1635","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.smim.2020.101430_bib1640","doi-asserted-by":"crossref","first-page":"14340","DOI":"10.1038\/ncomms14340","article-title":"Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity","volume":"8","author":"Zamarin","year":"2017","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.smim.2020.101430_bib1645","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.smim.2020.101430_bib1650","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1158\/1078-0432.CCR-19-0405","article-title":"Localized treatment with oncolytic adenovirus Delta-24-RGDOX induces systemic immunity against disseminated subcutaneous and intracranial melanomas","volume":"25","author":"Jiang","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.smim.2020.101430_bib1655","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2017","journal-title":"Gene Ther."},{"issue":"14","key":"10.1016\/j.smim.2020.101430_bib1660","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1158\/0008-5472.CAN-17-0468","article-title":"Oncolytic adenovirus and tumor-targeting immune modulatory therapy improve autologous Cancer vaccination","volume":"77","author":"Jiang","year":"2017","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.smim.2020.101430_bib1665","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1158\/0008-5472.CAN-09-2522","article-title":"Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1670","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrc2809","article-title":"Eicosanoids and cancer","volume":"10","author":"Wang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.smim.2020.101430_bib1675","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","article-title":"Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy","volume":"30","author":"Hou","year":"2016","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1680","doi-asserted-by":"crossref","DOI":"10.1016\/j.immuni.2019.07.003","article-title":"Oncolytic viruses engineered to enforce leptin expression reprogram tumor-infiltrating t cell metabolism and promote tumor clearance","volume":"51","author":"Rivadeneira","year":"2019","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.smim.2020.101430_bib1685","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.immuni.2019.08.010","article-title":"Leptin-producing oncolytic virus makes tumor-infiltrating t cells fit, not fat","volume":"51","author":"Kroemer","year":"2019","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.smim.2020.101430_bib1690","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aal1713","article-title":"Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells","volume":"2","author":"Dai","year":"2017","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.smim.2020.101430_bib1695","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2217\/fmb.15.19","article-title":"Polio vaccination: past, present and future","volume":"10","author":"Bandyopadhyay","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.smim.2020.101430_bib1700","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2147\/IJWH.S50365","article-title":"Long-term efficacy and safety of human papillomavirus vaccination","volume":"6","author":"De Vincenzo","year":"2014","journal-title":"Int. J. Womens Health"},{"key":"10.1016\/j.smim.2020.101430_bib1705","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113407","article-title":"Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus","author":"Froechlich","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.smim.2020.101430_bib1710","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2020.10.006","article-title":"Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment","author":"De Lucia","year":"2020","journal-title":"Mol Ther Oncolytics"}],"container-title":["Seminars in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044532320300464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:19:58Z","timestamp":1760915998000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044532320300464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":342,"alternative-id":["S1044532320300464"],"URL":"https:\/\/doi.org\/10.1016\/j.smim.2020.101430","relation":{},"ISSN":["1044-5323"],"issn-type":[{"value":"1044-5323","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New viral vectors for infectious diseases and cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.smim.2020.101430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101430"}}